A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Trial Profile

A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Dabrafenib; Trametinib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 14 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Apr 2017.
    • 14 Nov 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2017.
    • 02 Nov 2015 Planned End Date changed from 1 Mar 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top